Polyclonal Antibody Sequencing: LC-MS/MS Workflows, Accuracy, and Proteomics vs NGS

Polyclonal Antibody Sequencing in Complex Antibody Mixtures

Polyclonal antibodies are produced by multiple B-cell clones and usually bind multiple epitopes on the same antigen. This diversity is useful biologically, but it creates a major sequencing challenge. A polyclonal antibody sample is not one sequence; it is a mixture of related antibody species with different variable regions, CDRs, abundance levels, and sometimes different isotypes or subclasses.

In monoclonal antibody sequencing, the analytical task is usually to reconstruct one heavy chain and one light chain. In polyclonal antibody sequencing, the task may be to identify dominant antibody species, recover CDR evidence, reconstruct candidate monoclonal antibodies from a mixture, or compare the antibody protein population with a B-cell repertoire dataset.

The goal should be defined before the project begins. A project that asks "what are the dominant antigen-binding antibodies in this polyclonal reagent?" needs a different design from one that asks "does this commercial pAb lot contain reproducible protein-level evidence?" or "can we convert a pAb response into recombinant monoclonal candidates?"

Why Polyclonal Antibody Sequencing Is More Difficult Than Monoclonal Sequencing

The core difficulty is mixture complexity. Polyclonal antibodies share many framework and constant-region peptides, so the peptides that best define antibody identity are often found in variable regions and CDRs. Those regions may be low abundance, difficult to ionize, modified, short, or missing from a given digestion.

These issues explain why a routine peptide mapping workflow is not enough. Polyclonal antibody sequencing requires a strategy designed for mixture resolution, CDR evidence, and confidence scoring.

LC-MS/MS Proteomics Workflow for Polyclonal Antibody Sequencing

LC-MS/MS proteomics starts from antibody protein. This makes it useful when the actual antibody product is the material of interest, such as antigen-affinity purified pAbs, serum-derived antibodies, commercial polyclonal reagents, or legacy antibody mixtures where no matched cell source is available.

1. Sample assessment and antibody enrichment.
2. Optional antigen-affinity purification to reduce mixture complexity.
3. Fractionation or subunit preparation when needed.
4. Intact mass or subunit mass analysis to profile major antibody forms.
5. Multiple enzymatic digests for bottom-up peptide evidence.
6. Middle-down or top-down analysis when longer sequence context is needed.
7. LC-MS/MS acquisition with high-resolution fragmentation.
8. De novo peptide interpretation and database-assisted review where appropriate.
9. Assembly of candidate heavy/light chain regions and CDRs.
10. Confidence review, ambiguity reporting, and candidate prioritization.

Bottom-up MS provides many peptide-level observations, but short peptides can be difficult to connect across a complex mixture. Middle-down or intact/subunit mass analysis can add longer-range context and support grouping. Recent work integrating intact mass, middle-down, and de novo bottom-up MS shows why multiple evidence layers are important for pAb sequencing rather than relying on a single LC-MS/MS run (Xin et al., 2025).

For service-supported polyclonal antibody projects, this planning step is often where the most value is created. The project may require antigen enrichment, fractionation, multiple digests, CDR-focused review, or a combined proteomics/NGS interpretation plan rather than a generic antibody sequencing run.

How Accuracy Is Evaluated in Polyclonal Antibody Sequencing

Accuracy in polyclonal antibody sequencing should be evaluated locally and biologically, not only as a single global score. A sequence candidate may have strong framework evidence but weak CDR-H3 support, or strong peptide coverage but uncertain heavy/light chain pairing.

The most important regions depend on the project goal. For pAb-to-mAb conversion, CDRs and heavy/light pairing are central. For lot comparison, coverage patterns, dominant peptides, and reproducibility may be more important. For antigen-specific discovery, enrichment specificity and abundance ranking become critical.

Published pAb proteomics studies illustrate that peptide overlap, middle-down evidence, intact mass, and recombinant validation can all contribute to confidence (Le Bihan et al., 2024; Xin et al., 2025). In service work, the same principle applies: the report should explain why a candidate sequence is plausible and where uncertainty remains.

Proteomics vs NGS for Polyclonal Antibody Sequencing

Proteomics and NGS are complementary, not interchangeable. NGS reads nucleic acids from B cells, while LC-MS/MS reads the antibody proteins present in the sample. In polyclonal antibody projects, that difference matters.

NGS can produce a large list of candidate antibody sequences from B-cell material. However, not every transcript corresponds to a circulating antibody protein, and not every circulating antibody is represented in a peripheral B-cell sample at the time of collection. Proteomics directly interrogates the antibody protein pool, which is why it can reveal sequences not captured by B-cell repertoire data (Le Bihan et al., 2024).

The strongest strategy may combine both. NGS provides a candidate sequence database and codon-level information, while LC-MS/MS confirms protein-level presence, abundance, PTMs, and antigen-enriched antibody evidence.

When LC-MS/MS Proteomics Is More Informative Than NGS

LC-MS/MS proteomics becomes especially informative when the antibody protein sample is the primary or only available material. This is common in archived polyclonal reagents, commercial pAbs, antigen-affinity purified antibodies, immunized animal serum, or serum/plasma samples where no matched B cells are available.

LC-MS/MS is also the better route when the project requires protein-level evidence. If the question is whether a particular antibody species is actually present in the circulating IgG pool or in an affinity-purified fraction, MS evidence is more directly relevant than transcript evidence alone.

Proteomics can also provide information NGS cannot, such as oxidation, deamidation, glycosylation, terminal processing, clipping, and intact or subunit mass patterns. These features may matter for lot consistency, functional interpretation, and downstream recombinant testing.

When the sample is complex, Creative Proteomics can support project planning around enrichment, LC-MS/MS strategy, sequence confidence, and CDR review through related workflows such as LC-MS/MS-based antibody sequencing and de novo antibody sequencing.

When NGS or IgSeq Adds Value to Polyclonal Antibody Analysis

NGS adds value when matched B cells, PBMCs, lymphoid tissue, or high-quality RNA are available. It can capture broad repertoire diversity and provide many candidate variable-region sequences that may not be easily recovered from MS data alone.

NGS is especially useful when the goal is repertoire-scale discovery. It can show clonal families, somatic hypermutation patterns, V(D)J usage, codon-level sequence information, and potential heavy/light chain pairing if paired-chain or single-cell methods are used.

However, transcript-level abundance should not be treated as a direct substitute for protein abundance. Serum antibodies may originate from long-lived plasma cells that are not well represented in a peripheral blood draw. Timing, tissue source, immune state, and antigen enrichment all affect overlap between B-cell sequencing and the circulating antibody proteome.

For projects where both matched cells and antibody protein are available, a combined approach is often strongest: use NGS to define a candidate repertoire, then use LC-MS/MS proteomics to identify which candidates are present in the antibody protein mixture.

Common Failure Points in Polyclonal Antibody Sequencing

The most common failure point is insufficient enrichment. If the target antigen-specific antibodies are a small fraction of total IgG, the MS dataset may be dominated by unrelated antibodies. Antigen-affinity enrichment, fractionation, or targeted analysis may be required.

Low-abundance clones are another challenge. Dominant antibodies produce more spectra and stronger peptide coverage, while minor clones may remain below detection. A report should distinguish dominant sequence candidates from tentative low-abundance evidence.

CDR coverage can be incomplete. CDR-H3 is often the most difficult region because it is diverse, variable in length, and central to binding specificity. Missing CDR-H3 evidence can limit confidence even when framework peptides are abundant.

Heavy/light chain pairing is a major risk. A polyclonal sample may contain many heavy chains and many light chains. Pairing them incorrectly can generate recombinant candidates that look plausible but do not reproduce the original binding activity.

Shared peptides and isobaric ambiguity also require caution. Shared framework peptides can support multiple candidates, and standard MS/MS generally cannot distinguish Leu/Ile directly. These issues should be reported rather than hidden.

Sample Requirements and Project Planning for Polyclonal Antibody Sequencing

The best sample depends on the project goal. Antigen-affinity purified pAb is usually stronger for antigen-specific sequence discovery, while total serum IgG may be useful for repertoire-level protein profiling but is more complex.

Useful project metadata include antigen target, species, immunization history, purification method, antibody format, expected use case, lot number, and whether matched B-cell material is available. These details shape the workflow more than a generic "pAb sequencing" label.

Before submission, define the intended output: dominant mAb candidates, CDR evidence, lot comparison, antigen-specific sequence evidence, proteomics vs NGS comparison, or recombinant follow-up. The deliverable should match that goal.

Service-Supported Strategy for Complex Polyclonal Antibody Projects

Polyclonal antibody sequencing often needs a custom strategy rather than a standard single-sample workflow. The key service question is not simply "can this pAb be sequenced?" but "what evidence can this sample realistically support, and what workflow gives the best chance of answering the project question?"

Creative Proteomics can support pAb projects with sample triage, enrichment planning, LC-MS/MS workflow design, CDR evidence review, heavy/light chain reconstruction feasibility, and proteomics vs NGS route selection. For projects focused on binding-region recovery, antibody CDR sequencing and antibody light and heavy chain sequencing may help define the evidence level needed for candidate reconstruction.

For projects where matched cells are available, PCR-based antibody sequencing can complement protein-level MS by providing genetic sequence context. For protein-only or legacy samples, LC-MS/MS remains the more direct route to the antibody molecules present in the sample.

FAQs

1) Can polyclonal antibodies be sequenced by LC-MS/MS?

Yes. LC-MS/MS can sequence informative peptides from polyclonal antibody mixtures, especially after antibody enrichment or fractionation. Complete reconstruction of every antibody in a pAb mixture is not always realistic, so results should be interpreted by evidence level.

2) How is polyclonal antibody sequencing different from monoclonal sequencing?

Monoclonal sequencing usually reconstructs one heavy chain and one light chain. Polyclonal sequencing must resolve multiple related antibodies, shared peptides, abundance differences, CDR diversity, and heavy/light chain pairing.

3) Is proteomics or NGS better for polyclonal antibody sequencing?

Neither method is universally better. Proteomics reads the antibody proteins present in the sample, while NGS reads antibody transcripts from cells. The best method depends on available material and project goals.

4) Can LC-MS/MS identify all antibodies in a polyclonal mixture?

Not always. Dominant antibodies are more likely to be detected than low-abundance clones. Complex mixtures may require enrichment, fractionation, middle-down analysis, or NGS support.

5) How is heavy and light chain pairing handled in pAb sequencing?

Pairing can be supported by fractionation, intact or subunit mass, co-elution patterns, middle-down evidence, and recombinant validation. Pairing uncertainty should be reported clearly.

6) What determines accuracy in polyclonal antibody sequencing?

Accuracy depends on peptide coverage, CDR evidence, multi-protease overlap, intact or subunit mass agreement, chain-pairing support, spectral quality, and manual review of ambiguous regions.

7) Can CDRs be recovered from polyclonal antibodies?

Yes, CDRs can often be partially or fully recovered when peptide evidence is strong. CDR-H3 is usually the hardest region and should be supported by direct or overlapping evidence.

8) What sample type works best for pAb sequencing?

Antigen-affinity purified polyclonal antibody is usually the strongest starting material for antigen-specific analysis. Total serum IgG is more complex and often requires enrichment or additional fractionation.

9) When is matched NGS data useful?

Matched NGS data is useful when B cells, PBMCs, or RNA are available. It can provide a candidate repertoire database, codon-level sequence information, and broader clonal context for interpreting proteomics data.

10) Can pAb sequencing support recombinant monoclonal antibody recovery?

Yes, when enough evidence supports candidate heavy and light chain sequences and CDRs. Recombinant expression and binding validation are important follow-up steps before treating a recovered candidate as functionally equivalent.

For Research Use Only. Not for use in diagnostic procedures.

References

1. Le Bihan, T.; et al. (2024). De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nature Communications, 15, 8790.
2. Xin, L.; Li, W.; Zhang, S.; et al. (2025). Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle-Down, and De Novo Bottom-Up Mass Spectrometry. Molecular & Cellular Proteomics, 24, 101088.
3. de Graaf, S. C.; Hoek, M.; Tamara, S.; Heck, A. J. R. (2022). A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies. mAbs, 14, 2079449.
4. Snapkov, I.; Chernigovskaya, M.; Sinitcyn, P.; Le Quy, K.; Nyman, T. A.; Greiff, V. (2022). Progress and challenges in mass spectrometry-based analysis of antibody repertoires. Trends in Biotechnology, 40, 463-481.
5. Guthals, A.; et al. (2016). De Novo MS/MS Sequencing of Native Human Antibodies. Journal of Proteome Research, 15, 4200-4212.

For research use only, not intended for any clinical use.